GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of how much of what we believe about endpoint actually comes from TRIUMPH threads — 65 comments in the full submission. View in context.
3.3k
c/trialwatch·submitted 1 year ago by u/marit_laurent

how much of what we believe about endpoint actually comes from TRIUMPH threads

Discussionbranch of 8 comments

how much of what we believe about endpoint actually comes from TRIUMPH threads. I would rather ask a basic question now than get this wrong quietly for two months. Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about. Quoted a figure here…

Read the full submission and all 65 comments →

This branch

8 comments, started 1 year ago
u/sanne_laurent-4 points·1 year ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

replysharereportpermalink
u/slow_logbook_notes301 point·1 year ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

Agreed. And the interval, not the point estimate, is what the trial actually established.

replysharereportpermalink
u/marit_laurentOP-5 points·1 year ago

What was the comparator?

replysharereportpermalink
u/cold_chromatogram311 point·1 year ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

This is the distinction that would end about half the arguments on this board.

replysharereportpermalink
u/rania_salinas1 point·1 year ago

Which trial, and which arm?

replysharereportpermalink
u/marit_laurentOP1 point·1 year ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
u/arne_ilunga1 point·1 year ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/marit_laurentOP1 point·1 year ago

Do you have the publication or the press release?

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.